| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
Mirificin is natural product of the flavonoid class. Mirificin (Puerarin apioside) is a natually occuring isoflavone isolated from Puerariae Lobatae Radix. It inhibits tyrosinase (TYR) with an IC50 of 12.66 μM.
| Targets |
Tyrosinase (TYR) (IC50 = 12.66 ± 2.77 μM) [1]
|
|---|---|
| ln Vitro |
The tyrosinase inhibitory activity of Mirificin was measured spectrophotometrically, yielding an IC50 value of 12.66 ± 2.77 μM, indicating its ability to inhibit tyrosinase. The ranking of inhibitory activity among tested compounds was puerarin > Mirificin > kojic acid > daidzin ≈ genistin. [1]
Molecular docking studies using Glide 5.5 showed that Mirificin had a docking score of -6.04 and a binding energy of -51.65, which were higher (better) than those of the standard tyrosinase inhibitor kojic acid (score -5.87, energy -47.31). The docking pose of Mirificin within the catalytic active pocket of mushroom tyrosinase (PDB ID: 2Y9X) revealed interactions including π-π interaction with His263, cation-π interaction with His244, Van der Waals interaction with Val283, and hydrogen bonds with Asn260, His85, and Lys79. The binding is characterized by a lipophilic sandwich between Val248 and Val283. [1] |
| Enzyme Assay |
The tyrosinase inhibition assay was performed using a spectrophotometric method. The reaction mixture consisted of 50 μL of the ligand solution (the corresponding ligand standards were diluted 50-fold with phosphate-buffered saline, PBS) incubated with 50 μL of tyrosinase solution (0.1 U/mL) for 30 minutes at room temperature. Then, 100 μL of L-tyrosine (0.4 mM) was added and incubated for another 30 minutes at 30°C. Absorbance was measured in triplicate at 480 nm. The inhibition ratio was calculated using the formula: Inhibition Ratio (%) = (Ab - Ae)/Ab × 100%, where Ab and Ae represented the absorption of blank groups and experiment groups, respectively. [1]
The ultrafiltration screening parameters were optimized, including tyrosinase concentration (0.025, 0.05, 0.1, 0.2 mg/mL), incubation time (10, 20, 30, 40 min), incubation temperature (10, 20, 30, 40°C), and centrifugation speed (5000×g, 6000×g, 7000×g, 8000×g). For the tyrosinase-site blocking ultrafiltration screening (control group), 50 μL of tyrosinase (0.1 mg/mL) was incubated with 50 μL of kojic acid (0.05 mg/mL) for 30 minutes at 30°C to block the tyrosinase active site, followed by addition of PLR extract and the same procedure. The binding degree (BD) was calculated as BD (%) = (Sk - Se)/Sk × 100%, where Sk and Se represent peak areas of a compound in the blank and experiment groups, respectively, in HPLC chromatograms. [1] |
| References | |
| Additional Infomation |
Pueraria lobata extract is a flavonoid C-glycoside formed by the substitution of a 7,4'-dihydroxyflavone residue at the 8-position of the C-glycosidic bond with a 6-O-[(2R,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxacyclopentan-2-yl]-β-D-glucopyranose residue. It is a plant metabolite. It is both a dihydroxyflavone and a flavonoid C-glycoside. Pueraria lobata extract has been reported in kudzu root (Pueraria montana var. lobata), and relevant data are available.
Mirificin is a C-glycoside isoflavone. Structure-activity relationship analysis indicated that C-glycosides (such as puerarin and Mirificin) showed better tyrosinase inhibition compared to O-glycosides (daidzin and genistin). The addition of glycosyl moieties reduced tyrosinase inhibition due to steric hindrance and changes in polarity. Mirificin has additional glycosyl moieties compared to puerarin, and its IC50 (12.66 μM) was slightly higher (less potent) than that of puerarin (9.83 μM), suggesting that the presence of extra glycosyl groups decreases inhibitory activity. [1] |
| Molecular Formula |
C26H28O13
|
|---|---|
| Molecular Weight |
548.4927
|
| Exact Mass |
548.153
|
| CAS # |
103654-50-8
|
| PubChem CID |
21676217
|
| Appearance |
Off-white to light yellow solid
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
848.0±65.0 °C at 760 mmHg
|
| Flash Point |
285.8±27.8 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.749
|
| LogP |
1.21
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
39
|
| Complexity |
906
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O1[C@@]([H])(C2=C(C([H])=C([H])C3C(C(C4C([H])=C([H])C(=C([H])C=4[H])O[H])=C([H])OC2=3)=O)O[H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[C@@]1([H])[C@@]([H])([C@@](C([H])([H])O[H])(C([H])([H])O1)O[H])O[H])O[H])O[H])O[H]
|
| InChi Key |
ZBXWGKPUSLRPHX-QOIVFALESA-N
|
| InChi Code |
InChI=1S/C26H28O13/c27-9-26(35)10-38-25(24(26)34)37-8-16-19(31)20(32)21(33)23(39-16)17-15(29)6-5-13-18(30)14(7-36-22(13)17)11-1-3-12(28)4-2-11/h1-7,16,19-21,23-25,27-29,31-35H,8-10H2/t16-,19-,20+,21-,23+,24+,25-,26-/m1/s1
|
| Chemical Name |
8-[(2S,3R,4R,5S,6R)-6-[[(2R,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]-7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one
|
| Synonyms |
Puerarin apioside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8232 mL | 9.1159 mL | 18.2319 mL | |
| 5 mM | 0.3646 mL | 1.8232 mL | 3.6464 mL | |
| 10 mM | 0.1823 mL | 0.9116 mL | 1.8232 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
